- Home
- RDI vs BNR Comparison
RDI vs BNR Comparison
Compare RDI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- BNR
- Stock Information
- Founded
- RDI 1937
- BNR 2014
- Country
- RDI United States
- BNR China
- Employees
- RDI N/A
- BNR N/A
- Industry
- RDI Movies/Entertainment
- BNR Medical Specialities
- Sector
- RDI Consumer Discretionary
- BNR Health Care
- Exchange
- RDI Nasdaq
- BNR Nasdaq
- Market Cap
- RDI 27.9M
- BNR 38.3M
- IPO Year
- RDI N/A
- BNR 2020
- Fundamental
- Price
- RDI $1.32
- BNR $4.68
- Analyst Decision
- RDI
- BNR
- Analyst Count
- RDI 0
- BNR 0
- Target Price
- RDI N/A
- BNR N/A
- AVG Volume (30 Days)
- RDI 29.3K
- BNR 17.4K
- Earning Date
- RDI 08-13-2025
- BNR 08-21-2025
- Dividend Yield
- RDI N/A
- BNR N/A
- EPS Growth
- RDI N/A
- BNR N/A
- EPS
- RDI N/A
- BNR N/A
- Revenue
- RDI $205,644,000.00
- BNR $72,112,038.00
- Revenue This Year
- RDI $7.47
- BNR $136.32
- Revenue Next Year
- RDI $13.22
- BNR N/A
- P/E Ratio
- RDI N/A
- BNR N/A
- Revenue Growth
- RDI N/A
- BNR 0.53
- 52 Week Low
- RDI $1.17
- BNR $2.18
- 52 Week High
- RDI $1.89
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- RDI 53.64
- BNR 69.57
- Support Level
- RDI $1.27
- BNR $4.47
- Resistance Level
- RDI $1.36
- BNR $4.96
- Average True Range (ATR)
- RDI 0.06
- BNR 0.25
- MACD
- RDI 0.01
- BNR 0.11
- Stochastic Oscillator
- RDI 90.87
- BNR 84.31
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.